DBV Technologies Stock Drops After Announcing $150 Million Share Offering

Shares of DBV Technologies (NASDAQ:DBVT) fell on Monday after the biopharmaceutical company announced plans to sell up to $150 million of its American Depositary Shares (ADSs) through a refreshed at-the-market offering program.

Details of the Offering

DBV Technologies disclosed the plan in a shelf registration statement (Form S-3ASR) filed with the U.S. Securities and Exchange Commission. The filing establishes an at-the-market (ATM) program, which allows the company to sell shares directly into the open market from time to time at prevailing prices, rather than in a single, fixed-price transaction.

The refreshed program, managed by Citizens JMP Securities as the sales agent, carries forward previously registered but unsold ADSs and adds newly registered capacity to reach the $150 million total. According to the filing, each ADS represents five ordinary shares of the company.

Use of Proceeds

DBV Technologies intends to use the net proceeds from any sales to advance its lead product candidate, Viaskin Peanut. The company outlined several key objectives for the capital, including:

Ad

• Funding manufacturing expansion
• Supporting biologics license applications (BLAs) for children aged 1 through 7
• Preparing for the commercial launch of Viaskin Peanut for the 4-to-7 age group, contingent on regulatory approval

Funds will also be allocated to the development of other product candidates and for general working capital purposes, the company stated.

Market Impact

Following the announcement, DBV Technologies' stock price fell by 3.7%. The decline reflects a typical market reaction to potential shareholder dilution. When a company issues new shares, it increases the total number of shares outstanding, which can reduce the ownership percentage and earnings per share for existing investors.

For DBV, the capital raise is a strategic move to secure funding for critical pre-commercial and manufacturing activities as it seeks approval for its novel peanut allergy treatment. However, for investors, the immediate impact is the potential for their holdings to be diluted.